Table 1 Inclusion and exclusion criteria for IMPRESSION study

Provision of informed consent prior to any study-specific procedures

Provision of informed consent for angiography and PCI

Diagnosis of acute STEMI or acute NSTEMI

Male or non-pregnant female, aged 18 to 80 years old

Chest pain described by the patient as unbearable or patient’s request for analgesics

History of major surgery or severe trauma (within 3 months)

Prior morphine administration during the current STEMI or NSTEMI

Patients considered by the investigator to be at risk of bradycardic events

Treatment with ticlopidine, clopidogrel, prasugrel, or ticagrelor within 14 days before the study enrollment

Second- or third-degree atrioventricular block during screening for eligibility

Hypersensitivity to ticagrelor

Patient required dialysis

Current treatment with oral anticoagulant or chronic therapy with LMWH

History of asthma or severe chronic obstructive pulmonary disease

Active bleeding

Manifest infection or inflammatory state

History of intracranial hemorrhage

Killip class III or IV during screening for eligibility

Recent gastrointestinal bleeding (within 30 days)

Respiratory failure

History of coagulation disorders

History of severe chronic heart failure (NYHA class III or IV)

Concomitant therapy with strong CYP3A inducers (rifampicin, phenytoin, carbamazepine, dexamethasone, phenobarbital) within 14 days and during study treatment

Concomitant therapy with strong CYP3A inhibitors (ketoconazole, itraconazole, voriconazole, telithromycin, clarithromycin, nefazadone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir)

Hemoglobin concentration less than 10.0 g/dl

Platelet count less than <100 x10^3/mcl

History of moderate or severe hepatic impairment

Body weight below 50 kg